Janney Montgomery Scott Upped Its Ppl (PPL) Holding; Aduro BioTech, Inc. (ADRO) Had 2 Analysts Last Week

PPL Corporation (NYSE:PPL) Logo

Janney Montgomery Scott Llc increased Ppl Corp (PPL) stake by 6.1% reported in 2018Q4 SEC filing. Janney Montgomery Scott Llc acquired 30,824 shares as Ppl Corp (PPL)’s stock rose 4.89%. The Janney Montgomery Scott Llc holds 535,983 shares with $15.18M value, up from 505,159 last quarter. Ppl Corp now has $23.60B valuation. The stock increased 0.46% or $0.15 during the last trading session, reaching $32.74. About 11.54 million shares traded or 112.22% up from the average. PPL Corporation (NYSE:PPL) has risen 14.62% since March 17, 2018 and is uptrending. It has outperformed by 10.25% the S&P500. Some Historical PPL News: 20/03/2018 – PPL CORP PPL.N FY2018 SHR VIEW $2.31 — THOMSON REUTERS l/B/E/S; 20/03/2018 – PPL CORP – EXPECTS TO REAFFIRM COMPOUND ANNUAL EARNINGS PER SHARE GROWTH RATE OF 5% TO 6% THROUGH 2020; 08/05/2018 – HUHTAMAKI PPL LTD HUHT.NS – MARCH QTR TOTAL REVENUE FROM OPS 5.53 BLN RUPEES VS 5.62 BLN RUPEES YR AGO; 03/05/2018 – PPL Corp 1Q Adj EPS 74c; 03/05/2018 – PPL Corp 1Q EPS 65c; 03/05/2018 – PPL CORP PPL.N SEES FY 2018 SHR $2.11 TO $2.31; 16/05/2018 – PPL Corporation chairman says company remains well-positioned for future growth, success; 03/05/2018 – PPL Corp 1Q Rev $2.13B; 06/03/2018 PPL CORP PPL.N : RBC RAISES TO OUTPERFORM FROM SECTOR PERFORM; 15/05/2018 – Kempen Adds PPL, Exits Tapestry, Cuts New York Community: 13F

Among 2 analysts covering Aduro Biotech (NASDAQ:ADRO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aduro Biotech had 2 analyst reports since November 13, 2018 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Thursday, February 28. The rating was maintained by Canaccord Genuity on Tuesday, November 13 with “Buy”. See Aduro BioTech, Inc. (NASDAQ:ADRO) latest ratings:

28/02/2019 Broker: H.C. Wainwright Rating: Buy New Target: $7 Maintain
13/11/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $30 New Target: $10 Maintain

The stock increased 3.26% or $0.13 during the last trading session, reaching $4.12. About 695,126 shares traded. Aduro BioTech, Inc. (NASDAQ:ADRO) has declined 31.87% since March 17, 2018 and is downtrending. It has underperformed by 36.24% the S&P500. Some Historical ADRO News: 20/04/2018 – DJ Aduro BioTech Inc, Inst Holders, 1Q 2018 (ADRO); 05/03/2018 – ADURO MILESTONE FOR INITIATION OF PHASE I TRIAL OF ANTI-CD27; 03/04/2018 – Aduro Bio Presenting at Conference Apr 9; 17/04/2018 – Aduro Biotech Highlights Preclinical Data for Three Programs Reported at the American Association for Cancer Research Annual Meeting; 11/05/2018 – Harvard Adds Apple, Cuts Aduro Bio: 13F; 14/03/2018 – Aduro Biotech Announces Upcoming Data Presentations at the 2018 American Association for Cancer Research Annual Meeting; 05/03/2018 – Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors; 03/05/2018 – ADURO Strengthens Evidence-Based Health And Well-Being Team; 02/05/2018 – Aduro Biotech 1Q Loss/Shr 28c; 17/04/2018 – Aduro Biotech Plans to Initiate Phase 1 Study in Patients With Advanced Melanoma in 2H

More notable recent Aduro BioTech, Inc. (NASDAQ:ADRO) news were published by: Globenewswire.com which released: “Aduro Biotech Announces Upcoming Presentations at AACR Annual Meeting 2019 – GlobeNewswire” on February 28, 2019, also Globenewswire.com with their article: “Aduro Announces Changes to its Board of Directors – GlobeNewswire” published on February 21, 2019, Nasdaq.com published: “Aduro Biotech to Present at the 8th Annual SVB Leerink Global Healthcare Conference – Nasdaq” on February 21, 2019. More interesting news about Aduro BioTech, Inc. (NASDAQ:ADRO) were released by: Nasdaq.com and their article: “Aduro Biotech to Present at Two Upcoming Investor Conferences in March – Nasdaq” published on March 07, 2019 as well as Nasdaq.com‘s news article titled: “The Meet Group (MEET) to Report Q4 Earnings: What’s in Store? – Nasdaq” with publication date: March 01, 2019.

Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases. The company has market cap of $328.40 million. It is developing CRS-207, which has completed Phase Ib clinical trials for the treatment of unresectable malignant pleural mesothelioma; that has completed Phase II clinical trials for the treatment of pancreatic cancer; and that is in Phase I/II clinical trials for the treatment of ovarian cancer. It currently has negative earnings. The firm is also developing ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; ADU-741, which is in Phase I clinical trials for the treatment of prostate cancer; and a product candidate for the treatment of patients with cancers of the gastrointestinal tract.

More news for PPL Corporation (NYSE:PPL) were recently published by: Seekingalpha.com, which released: “PPL Corporation 2018 Q4 – Results – Earnings Call Slides – Seeking Alpha” on February 15, 2019. Investorplace.com‘s article titled: “3 Big Stock Charts for Tuesday: D. R. Horton, PPL and CF Industries – Investorplace.com” and published on March 05, 2019 is yet another important article.

Investors sentiment increased to 1.05 in Q4 2018. Its up 0.11, from 0.94 in 2018Q3. It is positive, as 42 investors sold PPL shares while 207 reduced holdings. 68 funds opened positions while 194 raised stakes. 520.88 million shares or 0.84% less from 525.30 million shares in 2018Q3 were reported. Cubist Systematic Strategies Ltd Liability invested in 0.1% or 76,019 shares. Peapack Gladstone accumulated 19,557 shares. M Secs Incorporated stated it has 11,004 shares or 0.1% of all its holdings. Maple stated it has 0.1% in PPL Corporation (NYSE:PPL). Argent Tru Co holds 30,989 shares. Community Bancorporation Na invested in 10,007 shares. Grisanti Cap Mgmt Limited Liability Corp has 206,312 shares for 3.8% of their portfolio. Assetmark holds 0% or 3,284 shares in its portfolio. Williams Jones & Limited Liability Co holds 0.01% or 16,594 shares in its portfolio. City Hldg has invested 0% in PPL Corporation (NYSE:PPL). Mackay Shields Lc invested 0.07% in PPL Corporation (NYSE:PPL). Brookstone Cap holds 0.04% or 18,560 shares in its portfolio. Farmers And Merchants Investments Inc has 0% invested in PPL Corporation (NYSE:PPL) for 1,868 shares. Greenleaf has invested 0% in PPL Corporation (NYSE:PPL). Great West Life Assurance Can holds 0.15% or 1.91 million shares in its portfolio.

Janney Montgomery Scott Llc decreased Valero Energy Corp (NYSE:VLO) stake by 12,115 shares to 52,240 valued at $3.92M in 2018Q4. It also reduced Epam Systems Inc (NYSE:EPAM) stake by 5,862 shares and now owns 11,967 shares. Ishs Acwi Ex Us Etf (ACWX) was reduced too.

PPL Corporation (NYSE:PPL) Institutional Positions Chart